FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385514079> ?p ?o ?g. }

• W4385514079 endingPage "27" @default.
• W4385514079 startingPage "22" @default.
• W4385514079 abstract "Anti-inflammatory drugs and biologics can effectively treat inflammatory conditions and diseases but can also cause burdensome side effects. Many patients prefer to use time-tested, traditional medicinal products and dietary supplements, but such products seldom receive the rigorous testing required for regulatory approvals of drugs and biologics. Thus, it is advantageous to demonstrate by experimentation the pharmacological and toxicological properties of unapproved natural products and compared to benchmark approved drugs or biologics.The studies intended to evaluate Samento®, a commercial hydro-alcoholic extract of the pentacyclic chemotype of Uncaria Tomentosa (Willd.) DC, for the prophylactic and treatment effects of irritant-induced inflammation and antigen-induced arthritic inflammation in two rat models. The studies were also intended to create a clinical bridge rationale for the use of Samento® in the treatment of inflammation in humans, with a suggested allometrically scaled starting dose.The research team performed two in vivo animal model studies of induced inflammation in rats.The studies took place at the Universidad Peruana Cayetano Heredia in Lima, Peru.Holtzman rats in five groups (five each per group) were administered 14 daily doses of Samento® at 250, 500, and 1000 mg/kg of wet weight, or 40 mg/kg of naproxen sodium as a positive control, or nothing as a negative control. At 14 days the right legs of the rats were challenged by injection into the connective tissue by the chemical irritant carrageenan. Two hours thereafter the weight of the irritant-injected right leg was compared to the non-injected left leg of each rat, to determine the level of irritant-induced inflammation.Arthritic inflammation was induced in five groups of Lewis rats (five each per group) by intradermal injection of the tail with non-allogeneic, bovine type II collagen in incomplete Freund's adjuvant. A sixth group was not injected with collagen antigen as a non-induced control. Ten days after the induction of arthritic inflammation in the five injected groups, individual groups were treated with Samento® at 250, 500, and 1000 mg/kg of wet weight daily for 21 days, or 0.2 mg/kg of methotrexate twice per week as a positive control, or nothing as a negative control. At 21 days the animals were assessed for antigen-induced arthritic inflammation and assigned an analog score ranging from 0 to 4.The research team confirmed the presence of pentacyclic oxindoles and the absence of tetracyclic oxindoles within Samento®. In the prophylactic model, 14 days of pretreatment with oral Samento® produced dose-dependent, statistically significant reductions in inflammation in the rats' leg weights between the carrageenan induction and postintervention, for the 250, 500, and 1000 mg/kg Samento® groups (P < .05 for all groups). The 1000 mg/kg group had a 74% anti-inflammatory effect versus 97% with the 40 mg/kg of naproxen sodium in the positive control group. In the treatment model, 21 days of oral administration of Samento® produced dose-dependent, statistically significant reductions in arthritic inflammation postintervention, for the 250, 500, and 1000 mg/kg Samento® groups (P < .05 for all groups). Treatment with the highest tested dose of the extract (1000 mg/kg) yielded an 85% anti-inflammatory effect versus 90% with 0.2 mg/kg of methotrexate in the positive control group.The two rat models revealed that the Uncaria phytotherapy Samento® was an effective prophylactic as well as a treatment for induced inflammation in rats. The highest dose of the pentacyclic chemotype of Uncaria approached the anti-inflammatory activities of the established benchmark pharmaceutical positive controls. The results in the two rat models suggest an allometrically scaled starting dose of Samento® of 4 g daily in humans." @default.
• W4385514079 created "2023-08-04" @default.
• W4385514079 creator A5004674117 @default.
• W4385514079 creator A5047924386 @default.
• W4385514079 creator A5051146150 @default.
• W4385514079 date "2023-07-01" @default.
• W4385514079 modified "2023-10-03" @default.
• W4385514079 title "Prophylaxis and Treatment of Inflammation with Pentacyclic Chemotype of Uncaria tomentosa." @default.
• W4385514079 cites W1481664342 @default.
• W4385514079 cites W1966758422 @default.
• W4385514079 cites W1980753303 @default.
• W4385514079 cites W2004212929 @default.
• W4385514079 cites W2007273075 @default.
• W4385514079 cites W2011259879 @default.
• W4385514079 cites W2014679542 @default.
• W4385514079 cites W2074261349 @default.
• W4385514079 cites W2076928396 @default.
• W4385514079 cites W2081932329 @default.
• W4385514079 cites W2086349186 @default.
• W4385514079 cites W2123755971 @default.
• W4385514079 cites W2202299430 @default.
• W4385514079 cites W2883382066 @default.
• W4385514079 cites W3081474706 @default.
• W4385514079 cites W39259311 @default.
• W4385514079 cites W4220791098 @default.
• W4385514079 cites W590313828 @default.
• W4385514079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37534020" @default.
• W4385514079 hasPublicationYear "2023" @default.
• W4385514079 type Work @default.
• W4385514079 citedByCount "0" @default.
• W4385514079 crossrefType "journal-article" @default.
• W4385514079 hasAuthorship W4385514079A5004674117 @default.
• W4385514079 hasAuthorship W4385514079A5047924386 @default.
• W4385514079 hasAuthorship W4385514079A5051146150 @default.
• W4385514079 hasConcept C142724271 @default.
• W4385514079 hasConcept C203014093 @default.
• W4385514079 hasConcept C204787440 @default.
• W4385514079 hasConcept C2776914184 @default.
• W4385514079 hasConcept C2778115740 @default.
• W4385514079 hasConcept C2778484676 @default.
• W4385514079 hasConcept C2779703632 @default.
• W4385514079 hasConcept C2781227287 @default.
• W4385514079 hasConcept C556039675 @default.
• W4385514079 hasConcept C71924100 @default.
• W4385514079 hasConcept C98274493 @default.
• W4385514079 hasConceptScore W4385514079C142724271 @default.
• W4385514079 hasConceptScore W4385514079C203014093 @default.
• W4385514079 hasConceptScore W4385514079C204787440 @default.
• W4385514079 hasConceptScore W4385514079C2776914184 @default.
• W4385514079 hasConceptScore W4385514079C2778115740 @default.
• W4385514079 hasConceptScore W4385514079C2778484676 @default.
• W4385514079 hasConceptScore W4385514079C2779703632 @default.
• W4385514079 hasConceptScore W4385514079C2781227287 @default.
• W4385514079 hasConceptScore W4385514079C556039675 @default.
• W4385514079 hasConceptScore W4385514079C71924100 @default.
• W4385514079 hasConceptScore W4385514079C98274493 @default.
• W4385514079 hasIssue "3" @default.
• W4385514079 hasLocation W43855140791 @default.
• W4385514079 hasOpenAccess W4385514079 @default.
• W4385514079 hasPrimaryLocation W43855140791 @default.
• W4385514079 hasRelatedWork W1909717111 @default.
• W4385514079 hasRelatedWork W1994505405 @default.
• W4385514079 hasRelatedWork W2022278689 @default.
• W4385514079 hasRelatedWork W2396618788 @default.
• W4385514079 hasRelatedWork W2423637028 @default.
• W4385514079 hasRelatedWork W2424481853 @default.
• W4385514079 hasRelatedWork W2522940298 @default.
• W4385514079 hasRelatedWork W2532185376 @default.
• W4385514079 hasRelatedWork W4214900223 @default.
• W4385514079 hasRelatedWork W1458926377 @default.
• W4385514079 hasVolume "22" @default.
• W4385514079 isParatext "false" @default.
• W4385514079 isRetracted "false" @default.
• W4385514079 workType "article" @default.